CARLSBAD, CA--(MARKET WIRE)--Jul 21, 2008 -- Invitrogen Corporation, a provider of essential life science technologies for research, production and diagnostics, and Active Motif, Inc., developer of TimeLogic® hardware-accelerated genomics solutions, have announced a joint project to explore the use of field programmable gate array (FPGA) technology for the analysis of next-generation sequencing data.
The TimeLogic search appliances couple an FPGA accelerator with optimized genomics algorithms to rapidly compare novel sequences to databases of well-characterized genes, helping scientists reveal the purpose and value of their sequence data. The TimeLogic solutions can deliver the performance of thousands of CPUs, yet are extremely power-efficient, require minimal maintenance, and can be “rewired” with software updates to ensure a long product lifespan.
Joe Fernandez, CEO of Active Motif, commented, “We look forward to working with Invitrogen to explore ways in which our technology can speed the processing of data directly from next-generation sequencing instruments, and to assess the physical requirements -- such as power consumption, cooling, data transfer, and space constraints -- that an optimal computational solution for research and clinical teams would require.”
About Active Motif, Inc.
Active Motif, founded in 1999, offers research kits, assays, and the TimeLogic® biocomputing systems to enable scientists to explore the relationships between genes, proteins and metabolic pathways. Active Motif is headquartered in Carlsbad, California, and has international offices in Tokyo, Japan and Brussels, Belgium. For more information, please visit www.activemotif.com and www.timelogic.com.
About Invitrogen
Invitrogen Corporation (IVGN - News) provides products and services that support academic and government research institutions and pharmaceutical and biotech companies worldwide in their efforts to improve the human condition. The company provides essential life science technologies for disease research, drug discovery, and commercial bioproduction. Invitrogen’s own research and development efforts are focused on breakthrough innovation in all major areas of biological discovery including functional genomics, proteomics, stem cells, cell therapy and cell biology -- placing Invitrogen’s products in nearly every major laboratory in the world. Founded in 1987, Invitrogen is headquartered in Carlsbad, California, and conducts business in more than 70 countries around the world. The company employs approximately 4,700 scientists and other professionals and had revenues of approximately $1.3 billion in 2007. For more information, visit www.invitrogen.com.
Contact:
Contact: Christopher Hoover Active Motif, Inc. TimeLogic Business Development (760) 431-1263 x350 Email Contact
Source: Active Motif, Inc.
